Close Menu

Now, Developer

23andMe has licensed an antibody it developed to treat inflammatory diseases to the Spanish drugmaker Almirall, according to Bloomberg

"This is a seminal moment for 23andMe," Emily Drabant Conley, the vice president of business development at 23andMe, tells Bloomberg. "We've now gone from database to discovery to developing a drug."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.